A post-international gastrointestinal cancers conference (IGICC) position statements '

Basit Öğe Kaydı
dc.authorscopusidNuri Faruk Aykan / 6507780121
dc.authorwosidNuri Faruk Aykan / I-6425-2019
dc.contributor.authorYalçın, Suayib
dc.contributor.authorLaçin, Şahin
dc.contributor.authorKaseb, Ahmed Omar
dc.contributor.authorPeynircioğlu, Bora
dc.contributor.authorCantaşdemir, Murat
dc.contributor.authorÇil, Barbaros Erhan
dc.contributor.authorHürmüz, Pervin
dc.contributor.authorDorul, Ahmet Bülent
dc.contributor.authorBozkurt, Murat Fani
dc.contributor.authorAbalı, Hüseyin
dc.contributor.authorAkhan, Okan
dc.contributor.authorŞimşek, Halis
dc.contributor.authorŞahin, Berksoy
dc.contributor.authorAykan, Nuri Faruk
dc.contributor.authorYücel, İdris
dc.contributor.authorTellioğlu, Gürkan
dc.contributor.authorSelçukbiricik, Fatih
dc.contributor.authorPhilip, Philip
dc.date.accessioned2025-04-18T07:34:02Z
dc.date.available2025-04-18T07:34:02Z
dc.date.issued2024
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, İSÜ Hastaneleri
dc.description.abstractHepatocellular carcinoma (HCC), the most prevalent liver tumor, is usually linked with chronic liver diseases, particularly cirrhosis. As per the 2020 statistics, this cancer ranks 6th in the list of most common cancers worldwide and is the third primary source of cancer-related deaths. Asia holds the record for the highest occurrence of HCC. HCC is found three times more frequently in men than in women. The primary risk factors for HCC include chronic viral infections, excessive alcohol intake, steatotic liver disease conditions, as well as genetic and family predispositions. Roughly 40-50% of patients are identified in the late stages of the disease. Recently, there have been significant advancements in the treatment methods for advanced HCC. The selection of treatment for HCC hinges on the stage of the disease and the patient's medical status. Factors such as pre-existing liver conditions, etiology, portal hypertension, and portal vein thrombosis need critical evaluation, monitoring, and appropriate treatment. Depending on the patient and the characteristics of the disease, liver resection, ablation, or transplantation may be deemed potentially curative. For inoperable lesions, arterially directed therapy might be an option, or systemic treatment might be deemed more suitable. In specific cases, the recommendation might extend to external beam radiation therapy. For all individuals, a comprehensive, multidisciplinary approach should be adopted when considering HCC treatment options. The main treatment strategies for advanced HCC patients are typically combination treatments such as immunotherapy and anti-VEGFR inhibitor, or a combination of immunotherapy and immunotherapy where appropriate, as a first-line treatment. Furthermore, some TKIs and immune checkpoint inhibitors may be used as single agents in cases where patients are not fit for the combination therapies. As second -line treatments, some treatment agents have been reported and can be considered.
dc.identifier.citationYalcin, S., Lacin, S., Kaseb, A. O., Peynircioğlu, B., Cantasdemir, M., Çil, B. E., ... & Philip, P. A. (2024). A Post-International Gastrointestinal Cancers’ Conference (IGICC) Position Statements. Journal of Hepatocellular Carcinoma, 953-974.
dc.identifier.doi10.2147/JHC.S449540
dc.identifier.endpage974
dc.identifier.pmid38832120
dc.identifier.scopus2-s2.0-85195117828
dc.identifier.scopusqualityQ4
dc.identifier.startpage953
dc.identifier.urihttp://dx.doi.org/10.2147/JHC.S449540
dc.identifier.urihttps://hdl.handle.net/20.500.12713/6453
dc.identifier.volume11
dc.identifier.wosWOS:001238803700001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.institutionauthorAykan, Nuri Faruk
dc.institutionauthoridNuri Faruk Aykan / 0000-0002-5472-3218
dc.language.isoen
dc.publisherDove medical press
dc.relation.ispartofJournal of hepatocellular carcinoma
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectHepatocellular Carcinoma
dc.subjectScreening
dc.subjectImaging
dc.subjectDiagnosis
dc.subjectTreatment
dc.subjectİmmunotherapy
dc.subjectTyrosine Kinase Inhibitors
dc.titleA post-international gastrointestinal cancers conference (IGICC) position statements '
dc.typeArticle

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

İSÜ Hastaneleri Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu